[Ian Schillebeeckx](https://www.linkedin.com/in/ian-schillebeeckx-5b87792a?trk=nav_responsive_tab_profile)		[ianschillebeeckx@gmail.com](mailto:ianschillebeeckx@gmail.com)		636.667.7425

**Vice President of Product						Dec 2017 \- Current**		  
*Cofactor Genomics, Inc*						*San Francisco, CA*

* Primary decision-maker of all product & technical considerations of 3 RNA-seq immuno-oncology diagnostic assays in a CAP/CLIA/GMP regulated environment:  
  * RUO Kit assay 1 launched with 6 molecular feature updates  
  * RUO LDT assay 2 launched from ideation in 12 months  
  * [Clinical LDT assay 3](https://cofactorgenomics.com/technology/) developed through 2nd clinical validation  
* Familiar with various assay techs (IHC, Flow, RNAseq, qPCR, DNAseq, MRD, cfDNA)  
* Created and managed 3/1 year development and validation roadmaps  
* Directly managed and mentored team of 10 biomarker and NGS scientists using OKRs and coordinated external lawyers, reagent vendors, CMO, and statistics/regulatory consultants  
* Designed and led CAP analytical validation of all assays  
* Established Palmetto MolDX validation strategy with limited precedent  
* 1st author on [CAP validation paper](https://www.sciencedirect.com/science/article/pii/S1525157820300167) and 1st author on [anti-PD1 biomarker *Nature* paper](https://www.nature.com/articles/s41598-022-05474-7)  
* Managed kit box manufacture and Contract Manufacturing Organizations to fill RUO Kit  
* Invented 3 RNAseq-based patents and managed company intellectual property  
* Setup design control system and wrote FDA breakthrough device designation application  
* Served as internal company expert on ISO/CLSI standards, immunology, medical oncology, statistics, and machine learning  
* Directed biomarker discovery in HNSCC, Lung, Bladder, Kidney, and Melanoma Cancers  
* Built relationships and collaborations with 30+ external collaborators and key opinion leaders  
* Designed and powered primary endpoints of 3, IRB-approved, [pre-specified clinical validation](https://classic.clinicaltrials.gov/ct2/show/NCT05296135) studies

**Founder, CEO								March 2017 \- Dec. 2017**  
*Where4Care*								*St. Louis, MO*

* Led team of 3 founders to launch a sms-based chatbot that recommends to patients where they should go to seek healthcare with the goal of reducing non-emergent care usage  
* worked with physicians to design validation and consented 200 patients at an Urgent Care

**Entrepreneur in Residence						Aug 2016 – May 2017**  
*Sling Health STL*								*St. Louis, MO*

* Led 4 teams of MD, PhD, MBA, and undergraduate university students in 4 simultaneous projects to create medtech commercial solutions for clinical problems: 1\) reducing non-emergent ER visits, 2\) tracking scratching with a wearable, 3\) cloud data analysis for legacy hospital machines, 4\) foot sizing / shoe recommendation mobile app using computer vision

**Vice President, President and CEO					June 2014 – Jan 2016**	  
*Sling Health STL								St. Louis, MO*

* Mentored 50+ clinical projects through problem definition, ideation, prototype, and launch  
* Led non-profit organization of 15+ volunteers across medical, business, and undergraduate schools that enabled 130+ students/year to solve clinical problems  
* Planned and raised $xxx,xxx budget and increased revenue by 200% over 2 years

**PhD Computer Science**						**Aug 2012 – Aug 2016**  
Washington University in St. Louis  
**BS Computer Science, BS Applied Mathematics		Aug 2007 – May 2011**  
Saint Louis University

**Publications**   
Multidimensional biomarkers predicts ... response … in HNSCC			JCO 2023  
[T Cell Subtype Profiling ... Predicts anti-PD-1 Response](https://www.nature.com/articles/s41598-022-05474-7)				Nature SR 2022  
[Analytical Performance of an Immunoprofiling Assay Based on RNA Models](https://www.sciencedirect.com/science/article/pii/S1525157820300167)	JMD 2020  
[Pose Hashing with Microlens Arrays](https://link.springer.com/chapter/10.1007/978-3-319-46487-9_37)							ECCV 2016  
[Single Image Camera Calibration … for Augmented Reality](https://www.computer.org/csdl/proceedings-article/cvpr/2016/8851d290/12OmNx0A7Bo)			CVPR 2016  
[The Geometry of Colorful Lenticular Arrays](https://ieeexplore.ieee.org/abstract/document/7335518)						3DV 2015  
[Structured Light Field Design for ... Rotation Estimation](https://ieeexplore.ieee.org/abstract/document/7168376)				ICCP 2015  
[Structure from Shadow Motion](https://ieeexplore.ieee.org/abstract/document/6831802)							ICCP 2014  
[Automated … synapse classification using … machine learning](https://www.sciencedirect.com/science/article/abs/pii/S0165027012004785)			J. Neurosci. 2013  
	  
**Patents**  
Artificial Intelligence Methods to Predict Immune Response			2022, in review  
Methods … to Determine Cellular States						2020  
[Methods … Of Processing Complex Data Using AI and Deconvolution](https://patents.google.com/patent/US20210133592A1/en)		2020, PCT  
[Immuno-oncology Applications Using Next Generation Sequencing](https://patents.google.com/patent/US10636512B2)		2018  
	  
**Miscellaneous**  
Belgian/American dual citizen  
Legal status to work in Europe and United States  
Colloquially fluent in French, intermediate in Spanish, previous exposure to Dutch and German  
Experience in optics, inertial measurement, PCB design, and carbon composites.

